Facility Details

The Drug Discovery Core (DDC) at the Miami Project to Cure Paralysis leverages the PerkinElmer Opera Phenix Plus high content screening system to provide researchers with state-of-the-art assay development and phenotypic screening capabilities. The core facility is also equipped with a PerkinElmer Janus G3 liquid handler, featuring modular and variable dispense heads, to automate screening workflows and enhance throughput.

The core supports a wide range of phenotypic and target-based assays. Phenotypic assays range from 2D to 3D, widefield to confocal, and antibody to dye based. It collaborates with users to develop customized assays and analytical pipelines tailored to their specific needs. Current specializations include neurite tracing, lipid droplet quantification, cell viability, morphological and kinetic analyses, phagocytosis, cell marker detection, cell adhesion, among others.